AB Science S.A. (OTCMKTS:ABSCF – Get Free Report) was the target of a significant decline in short interest in the month of June. As of June 15th, there was short interest totaling 1,000 shares, a decline of 99.3% from the May 31st total of 140,570 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.
AB Science Stock Performance
Shares of ABSCF remained flat at $1.12 during mid-day trading on Thursday. The firm has a 50-day moving average of $1.18 and a two-hundred day moving average of $1.34. AB Science has a 52 week low of $1.12 and a 52 week high of $1.37.
AB Science Company Profile
AB Science is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the discovery and development of protein kinase inhibitors. Its core focus is on the design of orally administered small-molecule therapies that target key signaling pathways involved in oncology, inflammatory disorders and neurodegenerative diseases. The company’s lead asset, masitinib, is a selective tyrosine kinase inhibitor that has been evaluated in multiple Phase 2 and Phase 3 clinical trials, including studies in mastocytosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and severe asthma.
Since its founding in 2001 by Dr.
Recommended Stories
- Five stocks we like better than AB Science
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for AB Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AB Science and related companies with MarketBeat.com's FREE daily email newsletter.
